Get the content you want anytime you want.
The Best Infectious Disease News Delivered Weekly

The Contagion® HIV / AIDS specialty page provides HIV/AIDS-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.


Is Cabotegravir a Gender-Neutral PrEP Medication?
Alex Rinehart, PhD, explains how cabotegravir is a gender-neutral pre-exposure prophylaxis medication.
Societal Challenges Keep At-risk Individuals from Taking PrEP
Kenneth Mayer, MD, discusses some societal challenges that at-risk individuals face today that may keep them from taking pre-exposure prophylaxis.
What is the Population-based HIV Impact Assessment Project?
Jessica Justman, MD, explains the PHIA Project (population-based HIV impact assessments).
How is Janssen's New HIV-1 Vaccine Regimen Unique?
Hanneke Schuitemaker, PhD, explains what makes Janssen’s new HIV-1 vaccine regimen unique.
What Makes Cabotegravir a Unique Medication for HIV?
Alex Rinehart, PhD, Director, Global Prevention Strategy, ViiV Healthcare, explains what makes cabotegravir a unique medication for HIV.
How Can Primary Care Providers Help Their Patients Decide if PrEP Is Right for Them?
Kenneth Mayer, MD, explains why primary care providers need to have a good sense of their patients in order to help them decide if PrEP is right for them.
Who Are the Core Partners Involved in the Fast-Track Cities Initiative?
Benjamin Young, MD, PhD, discusses the four partners behind the Fast-Track Cities Initiative.
New Formulation of Raltegravir HD Explained
Pedro Cahn, MD, explains the new formulation of raltegravir HD.
The new test can differentiate between Lyme disease and 7 other tick-borne diseases.